Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting. The event will take place from September 19-21 in Minneapolis, Minnesota.
Dr. David Brogan from Washington University will deliver the presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injury: A Phase 2 Randomized Controlled Trial, on Thursday, September 19, during the Academic Papers session. This presentation, selected as a Top 10 Best Paper, will showcase interim findings from a 24-week analysis of the NEUROFUSE study, which examines the safety and efficacy of NTX-001 in treating patients with acute, single-transection upper extremity peripheral nerve injuries.
NTX-001, a drug-device combination, aims to enhance both the speed and durability of functional recovery when used alongside standard surgical repair. These interim results represent a key milestone in the development of NTX-001 as a groundbreaking treatment for peripheral nerve injuries.
Key findings at 24 weeks include:
- NTX-001 led to greater improvements in MHQ (Michigan Hand Outcomes Questionnaire) total scores at 8 and 24 weeks post-surgery compared to the standard of care (SOC) alone.
- No safety concerns related to NTX-001 were observed.
- Patients treated with NTX-001 experienced significantly reduced postoperative pain at all time points compared to SOC alone.
These results indicate NTX-001’s potential to enhance functional recovery in peripheral nerve injury patients and warrant continued development.
“Traumatic peripheral nerve transection remains an unresolved challenge in hand and upper extremity surgery,” said Dr. Brogan, the study’s lead author and principal investigator at Washington University in St. Louis. “The use of PEGplasty in addressing this issue has sparked great interest among clinicians.”
Evan Zannis, Chief Operating Officer and Head of Research and Development at Neuraptive Therapeutics, added, “We are excited to share these promising interim results at such an important scientific forum and look forward to presenting full results in the future. Our gratitude goes out to the investigators, clinical site staff, our team, and, most importantly, the patients who took part in this study.
